Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Účinky konzumace testovacího přípravku na močení u zdravých japonských dospělých

29. září 2026 aktualizováno: Indena S.p.A

Efekty konzumace testovaného produktu na močení u zdravých japonských dospělých: Randomizovaná, placebem kontrolovaná, dvojitě zaslepená, paralelně skupinová komparační studie

The goal of this clinical trial is to test in Japanese adults who experience concerns regarding urinary frequency. The main question it aims to answer is:

•Does consumption of Cranberry Phospholipids reduce daytime urinary frequency?

Participants will be given the following tasks:

  • Take two tablets daily containing Cranberry Phospholipid for eight weeks.
  • Answer the questionnaire on the overactive bladder (OAB)-specific quality of life (QOL).
  • Answer the questionnaire on OAB symptoms.
  • Answer the questionnaire on urinary frequency during the study period. Researchers will compare Cranberry Phospholipids and placebo groups to see if Cranberry Phospholipids reduces daytime urinary frequency.

Přehled studie

Typ studie

Intervenční

Zápis (Odhadovaný)

76

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

Studijní místa

    • Tokyo
      • Nerima-ku, Tokyo, Japonsko, 176-0002
        • Nábor
        • Nerima Medical Association Minami-machi Clinic
        • Kontakt:
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Masafumi Nagata, MD
      • Shinagawa-Ku, Tokyo, Japonsko, 141-0022
        • Nábor
        • Medical Corporation Seishinkai, Takara Clinic
        • Kontakt:
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Tsuyoshi Takara, MD

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Japanese
  • Men or women
  • Adults
  • Healthy individuals
  • Individuals with positive urine leukocytes at baseline
  • Individuals whose score of urinary urgency of overactive bladder symptom score (OABSS) is less than two or total score of OABSS is less than three at baseline
  • Individuals whose "frequent urination during the daytime hours" of "symptom bother" of OAB-q is relatively high at baseline

Exclusion Criteria:

  • Individuals undergoing medical treatment or having a medical history of malignant tumor, heart failure, or myocardial infarction
  • Individuals carrying a pacemaker or an implantable cardioverter defibrillator
  • Individuals undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, kidney disease, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
  • Individuals who use or take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage as part of their daily diet
  • Individuals currently regularly taking medications (including herbal medicines) and supplements
  • Individuals who are allergic to medicines and/or the test-product-related products in this trial
  • Individuals with urinary pain
  • Individuals undergoing treatment, have had treatment within two months, or need the treatment for diseases related to urination, e.g. benign prostatic hypertrophy, prostatitis, prostate cancer, overactive bladder, hypoactive bladder, cystitis, interstitial cystitis, bladder cancer, bladder stones, urethritis, urethral stricture, neurological disease, polyuria, and nocturnal polyuria
  • Individuals have overactive bladder symptom (individuals who urinate eight times or more per day, and have urinary urgency at least once a week)
  • Individuals wake up twice or more to urinate at bedtime
  • Individuals are pregnant, breast-feeding, and planning to become pregnant
  • Individuals have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial
  • Individuals are judged as ineligible to participate in the trial by the physician

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Jiný
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Čtyřnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: Cranberry Phospholipids

Take two tablets (containing 120 mg cranberry phospholipids/tablet)

Take two tablets will be taken once daily

Komparátor placeba: Placebo

Take two tablets (containing 0 mg cranberry phospholipids/tablet)

Take two tablets will be taken once daily

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Measured value for the Overactive Bladder Questionnaire (OAB-q) questionnaire item "frequent urination during the daytime hours" after the 8-week intervention
Časové okno: After the 8-week intervention

Using OAB-q, we evaluate OAB-specific quality of life (QOL). The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL.

After the 8-week intervention

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Individuals whose the response to the OAB-q questionnaire item "frequent urination during the daytime hours" improved by one or more scale points after the 8-week intervention compared to Baseline
Časové okno: Baseline, and after the 8-week intervention

Using OAB-q, we evaluate OAB-specific QOL. The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL.

Baseline, and after the 8-week intervention
The amount of change, and percentage of change from Baseline for the OAB-q questionnaire item "frequent urination during the daytime hours" after the 8-week intervention
Časové okno: Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention

Using OAB-q, we evaluate OAB-specific QOL. The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL.

Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention
The measured values, amount of changes, and percentage of changes from Baseline for all other questionnaire items of the OAB-q, excluding "frequent urination during the daytime hours," after the 8-week intervention
Časové okno: Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention

Using OAB-q, we evaluate OAB-specific QOL. The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL.

Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention
The measured values, and amount of changes and percentage of changes from Period 1 for the average frequency of urination during the daytime, during the nighttime, and all day, as measured during Periods 2 to 9
Časové okno: Period 1 (7 days prior to Baseline), Period 2~9 (periods separated by 7 days from the start of intervention)

Participants will maintain a daily diary of their urination frequency during two distinct periods: for 7 days immediately preceding the Baseline, and from the beginning of the intervention until the day before the final examination.

Period 1 (7 days prior to Baseline), Period 2~9 (periods separated by 7 days from the start of intervention)
Individuals who experienced adverse events
Časové okno: After the 8-week intervention

During the trial period, if a participant exhibits any clinically significant "new manifestation of abnormality" or "aggravation" in his/her physical signs and symptoms, it is considered to be an adverse event.

After the 8-week intervention
Individuals whose values of urinalysis and peripheral blood test are outside the reference range after intervention despite within the reference range at Baseline
Časové okno: Baseline, and after the 8-week intervention

The ratio of cases which had test items stated in urinalysis and peripheral blood examination within their respective standard ranges before intervention but exceeded the ranges after intervention are calculated, intergroup comparison at each time point is performed using tests for comparing proportions.

Baseline, and after the 8-week intervention
Body height
Časové okno: Baseline, and after the 8-week intervention

Body height is measured using a height meter.

Baseline, and after the 8-week intervention
Body weight
Časové okno: Baseline, and after the 8-week intervention

Body weight is measured using a body scale.

Baseline, and after the 8-week intervention
Blood pressure
Časové okno: Baseline, and after the 8-week intervention

Systolic and diastolic blood pressure are measured using a digital wrist-type sphygmomanometer.

Baseline, and after the 8-week intervention
Urinalysis
Časové okno: Baseline, and after the 8-week intervention

A urine sample (approximately 10 mL) will be collected from each participant, and the samples will be sent to LSI Medience Corporation for analysis.

Baseline, and after the 8-week intervention
Peripheral blood examination
Časové okno: Baseline, and after the 8-week intervention

A venous blood sample (approximately 10 mL) will be collected from each participant, and the samples will be sent to LSI Medience Corporation for analysis.

Baseline, and after the 8-week intervention

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Studijní židle: Tsuyoshi Takara, MD, Medical Corporation Seishinkai, Takara Clinic

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

8. prosince 2025

Primární dokončení (Odhadovaný)

30. března 2027

Dokončení studie (Odhadovaný)

30. dubna 2027

Termíny zápisu do studia

První předloženo

21. ledna 2026

První předloženo, které splnilo kritéria kontroly kvality

30. ledna 2026

První zveřejněno (Aktuální)

6. února 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

30. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

29. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další identifikační čísla studie

  • 01170-0018-29
  • UMIN000060011 (Identifikátor registru: UMIN-CTR)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Popis plánu IPD

Data sharing will be discussed among the research affiliates after the study is completed.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit